Payment overview · 2025
General Payments
$314.23
13 reported records · 5 companies
Healthcare provider profile · identity verified
Jeffrey Steven Alexander, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOWSON, MD · NPI 1659479178
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Steven Alexander, MD received $314.23 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.32 | 52.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.34 | 16.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.63 | 15.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.67 | 9.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.27 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.23 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.09 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.34 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.63 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.67 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 85 |
| Losartan Potassium | Losartan Potassium | 223 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 50 |
| Eliquis | Apixaban | 167 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 44 |
| Trazodone Hcl | Trazodone Hcl | 156 | 31 |
| Famotidine | Famotidine | 121 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 33 |
| Gabapentin | Gabapentin | 111 | 39 |
| Celecoxib | Celecoxib | 108 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 24 |
| Tramadol Hcl | Tramadol Hcl | 94 | 25 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Lisinopril | Lisinopril | 92 | 28 |
| Methylprednisolone | Methylprednisolone | 92 | 66 |
| Spironolactone | Spironolactone | 90 | 30 |
| Ozempic | Semaglutide | 87 | 16 |
| Ezetimibe | Ezetimibe | 80 | 23 |
| Irbesartan | Irbesartan | 80 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 25 |
| Meloxicam | Meloxicam | 78 | 39 |
| Mounjaro | Tirzepatide | 73 | suppressed |
| Allopurinol | Allopurinol | 72 | 15 |
| Omeprazole | Omeprazole | 67 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 65 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 14 |
| Prednisone | Prednisone | 61 | 41 |
| Furosemide | Furosemide | 56 | 19 |
| Metformin Hcl | Metformin Hcl | 53 | 15 |
| Clonazepam | Clonazepam | 52 | 12 |
| Azithromycin | Azithromycin | 51 | 36 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 28 |
| Simvastatin | Simvastatin | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Tadalafil | Tadalafil | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.23 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Leqembi, Ozempic, QULIPTA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error